ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1490

High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis
Abstract Number: 1701

High TNFAIP3-Transfected Cell Activity: An In Vitro Model for Phagocyte Study of Monogenic Behçet’s Disease Pathophysiology
Abstract Number: 0563

High-Dimensional Immunophenotyping with Mass Cytometry Reveals Unique Immune Cell Aberrations in Patients with Undiagnosed Inflammatory and Autoimmune Diseases
Abstract Number: 0310

Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis
Abstract Number: 0449

Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis
Abstract Number: 2252

Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
Abstract Number: 1181

Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis
Abstract Number: 1885

Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
Abstract Number: 1299

Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children
Abstract Number: 0774

HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
Abstract Number: 0743

Home-Based Telehealth in Rheumatology: A Systematic Review & Narrative Synthesis
Abstract Number: 1871

Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Abstract Number: PP10

How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
Abstract Number: PP13

How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
Abstract Number: 1368

How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].